Recently approved diabetes drugs -- including Merck & Co.'s Januvia and Janumet, Novo Nordisk's Victoza and Bristol-Myers Squibb's Byetta and Bydureon -- are under FDA scrutiny as pancreatic tissue samples in patients who took the medications showed inflammation and cellular changes associated with cancer onset. "FDA has not concluded these drugs may cause or contribute to the development of pancreatic cancer. At this time, patients should continue to take their medicine as directed until they talk to their health care professional," the agency said.
FDA reviews new diabetes drugs to assess cancer risk
SmartBrief Job Listings for Health Care
|Sr. Medical Device Reimbursement Specialist - Regional||
|Fort Worth , TX|
|Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group||
|Clinical Trials Agreements Specialist (209955)||
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
|SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST||
Matheson Tri-Gas, Inc.
ASAHI INTECC, Orange County CA R&D Center
|Santa Ana, CA|